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Abstract 
Novel drugs such as bortezomib and high-
dose  chemotherapy  combined  with  stem  cell
transplantation improved the outcome of multi-
ple  myeloma  patients  in  the  past  decade.
However,  multiple  myeloma  often  remains
incurable due to the development of drug resist-
ance  governed  by  the  bone  marrow  micro  -
  environment.  Therefore  targeting  new  path-
ways  to  overcome  this  resistance  is  needed.
Histone deacetylase (HDAC) inhibitors repre-
sent  a  new  class  of  anti-myeloma  agents.
Inhibiting HDACs results in histone hyperacety-
lation and alterations in chromatine structure,
which, in turn, cause growth arrest differentia-
tion  and/or  apoptosis  in  several  tumor  cells.
Here we summarize the molecular actions of
HDACi as a single agent or in combination with
other drugs in different in vitro and in vivo
myeloma models and in (pre-)clinical trials.
Introduction
Multiple  myeloma  (MM)  is  a  plasma  cell
malignancy, characterized by an accumulation
of monoclonal plasma cells in the bone marrow
(BM)  and  high  levels  of  monoclonal  immu  -
  noglobulines  or  paraprotein  in  blood  and/or
urine. Complex interactions between MM cells
and the BM microenvironment are required for
the growth and progression of MM and result
in the development of drug resistance, angio-
genesis  and  induction  of  bone  disease.
1-4
Enhanced  understanding  of  the  interactions
between MM and the BM microenvironment
has led to the identification of new molecular
targets.  Novel  therapeutic  approaches  target
growth factors [e.g. insulin-like growth factor-
1  (IGF-1),  interleukin-6  (IL-6)  and  vascular
endothelial growth factor (VEGF)], adhesion
molecules and signaling cascades in the MM
cells  such  as  the  mitogen-activated  protein
kinase kinase (MEK)/extracellular signal regu-
lated  kinase  (ERK)-pathway,  the  phos-
phatidylinositol-3  kinase  (PI3K)/  protein
kinase B (Akt)-pathway, the nuclear factor ʺ B
(NFʺB)-pathway  and  the  Wnt-pathway.
5,6
Moreover, cells interacting with the MM cells
in the BM, such as stromal cells, endothelial
cells,  osteoblasts,  osteoclasts  and  mesenchy-
mal  stem  cells  are  also  potential  targets  to
overcome the drug resistance against conven-
tional chemotherapy.
7,8
MM represents 1% of all cancers and it is the
second most commonly diagnosed hematologic
malignancy.  The  incidence  is  higher  with
increasing age and is 4-5 per 100,000 individu-
als each year worldwide. The median age at
diagnosis is 67 years.
9 The most common clin-
ical characteristics in MM are bone pain, ane-
mia, recurrent infections and renal failure.
10
The standard induction therapy for elderly
patients with symptomatic myeloma, and who
are not candidates for stem cell transplantion,
used to be melphalan (M) and prednisone (P).
Recently,  improved  effects  on  survival  have




®)  (MPV)  or  thalidomide
(MPT).
11 Only the latter has been accepted as
standard  therapy.  High-dose  therapy  plus
autologous stem cell transplantation is consid-
ered the standard therapy for front-line treat-
ment of MM patients aged <65 years.
12,13 The
most  common  pre-transplantation  induction
therapies used today are thalidomide-dexam-
ethasone,  bortezomib-based  regimes,  and
lenalidomide-dexamethasone.
14,15 New  agents
such as bortezomib, thalidomide and lenalido-
mide in the treatment of MM do not only tar-
get the MM cells directly, but also influence
the interactions of the MM cells with the BM
microenvironment.  Combining  these  new
agents with conventional chemotherapy and
high-dose  chemotherapy  with  autologous
stem  cell  transplantation  increases  the  out-
come of MM patients, although eventually all
MM patients relapse. Therefore, identification
of new key molecules in MM cells and in the
BM microenvironment is crucial for the devel-
opment of new therapeutic strategies.
There  is  growing  evidence  that  not  only
gene defects such as deletions, mutations and
chromosomal  abnormalities  are  responsible
for  the  onset  and  progression  of  cancer.
Several  studies  have  shown  that  epigenetic
changes,  i.e.  heritable  traits  mediated  by
changes  in  DNA  other  than  nucleotide
sequences, play a key role in the downregula-
tion of tumor suppressor genes and/or upregu-
lation  of  oncogenes  and,  therefore,  are  also
involved in the onset and progression of sever-
al  malignancies.
16,17 Chromatin  remodeling  is
one of the main processes in epigenetic regu-
lations. Nucleosomes are the repeating units
of  chromatin  which  contain  146  bp  DNA
wrapped  around  a  core  histone  octamer.
Modifications  of  these  nucleosomes  on  the
histone level, as well as the DNA level, can
alter the chromatin state which can be open or
closed. The post-translational modifications on
the  core  histones  are  most  common  on  the
amino-terminal lysine rich tail which passes
through and around the enveloping DNA dou-
ble helix.
18 These modifications, such as acety-
lation, methylation, ubiquitinylation, sumoyla-
tion,  phosphorylation  and  glycosylation  are
crucial in modulating gene expression, as they
affect the accessibility and interaction of DNA
with other non-histone protein complexes that
could contain transcriptionally co-activating or
co-repressing elements.
19,20 More  o  ver, methyla-
tion  of  DNA,  maintained  by  the  epigenetic
enzymes,  methyltransferases  and  demethy-
lases,  also  affects  the  chromatin  structure
indirectly by recruiting protein complexes con-
taining enzymes such as histone deacetylases
(HDAC).
21 HDAC and the opposite enzyme his-
tone  acetyltransferases  (HAT)  are  the  most
analyzed enzymes involved in the post-transla-
tional modifications of histones. Both enzymes
maintain the acetylation status of histones and
non-histone proteins. HAT acetylates histones
resulting in neutralizing the positive charge of
histones and a more relaxed, transcriptionally
active  chromatin,  while  HDAC  remove  the
acetyl group resulting in a more compact, tran-
scriptionally  inactive  chromatin  structure.
22
Inhibiting HDAC leads to hyperacetylation of
histones and results in gene expression alter-
ation. In tumor cells, several HDAC inhibitors
(HDACi)  have  shown  promising  anti-cancer
activities with anti-proliferative, pro-apoptotic
and anti-angiogeneic properties.
23-28
This  review  provides  an  overview  of  the
anti-myeloma  activity  of  different  HDACi  in
pre-clinical settings and the latest clinical tri-
als with HDACi ongoing in MM patients. 
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Eighteen  HDACs  have  been  identified  in
humans and are subdivided into four classes
based on their homology to yeast HDACs and
their enzymatic activities.
29,30 Class I HDACs (1,
2, 3 and 8) are homologs to the yeast Rpd3 and
can generally be detected in the nucleus. They
are ubiquitously expressed in several human
cell lines and tissues. Based on phylogenetic
analysis, Gregoretti et al. divided class I into Ia
(HDAC1 and 2), Ib (HDAC3) and Ic (HDAC8).
31
Class II HDACs (4, 5, 6, 7, 9 and 10) are relat-
ed to yeast Hda1 (histone deacetylase 1) and
can  shuttle  between  the  nucleus  and  cyto-
plasm.  This  class  is  divided  into  class  IIa
(HDACs 4, 5, 7 and 9) and class IIb (HDAC6
and  10)  which  contain  two  deacetylase
domains.
30 Since  HDAC6  contains  a  unique
alpha-tubulin deacetylase (TCAD) domain, it
can  specifically  deacetylate  alpha-tubulin.
32
The third class HDACs are the sirtuins (SIRT
1, 2, 3, 4, 5, 6 and 7) which are homologs to the
yeast  Sir2  (silent  information  regulator  2)
family. These enzymes require nicotine ade-
nine dinucleotide (NAD)
+ for their deacetylase
activity in contrast to the zinc-catalyzed mech-
anism used in class I and II HDACs.
29 The sir-
tuins appear to deacetylate non-histone pro-
teins and transcription factors including p53.
They can not be inhibited by HDACi such as
suberoylanilide  hydroxamic  acid  (SAHA)  or
Trichostatin  A  (TSA).
33 HDAC11  represents
class IV and contains residues in the catalytic
core  regions  similar  to  both  class  I  and  II
enzymes  but  does  not  have  strong  enough
identity to be placed in either class.
34
HDAC inhibitors
Structural classification of HDAC inhibitors
Butyrate  and  TSA  were  among  the  first
chemicals to be identified as HDAC inhibitors.
Dimethylsulfoxide was used to aid superinfec-
tion of murine erythroleukemia cells with the
Friend virus, whereas TSA was originally iso-
lated as an antifungal agent from culture medi-
um of Streptomyces hygroscopicus. Later on, it
was  discovered  that  these  compounds  could
induce  cell  differentiation  and  a  correlation
with  histone  hyperacetylation,  which  was
maintained  by  inhibiting  HDACs,  could  be
shown.
35-39 It subsequently opened a new field
of research. Since then, a large number of nat-
ural and synthetic HDACi have been developed
by several companies and used as anti-tumor
agents  in  pre-clinical  and  clinical  settings
(Table 1). On the basis of their chemical struc-
ture, major HDACi can be divided into four cat-
egories: short-chain fatty acids, hydroxamates,
benzamides and cyclic tetrapeptides.
26,46,47
Among the various classes of HDACi, short
chain fatty acids such as phenylbutyrate, the
anti-epileptic  drug  valproic  acid  (VPA)  and
sodium butyrate are only effective at mM con-
centrations and thereby form the less potent
class  of  HDACi.
41 Clinical  evaluations  have
been performed with these compounds either
alone or in combination and are well tolerated
in patients. However due to the short plasma
half-life,  high  doses  are  needed  to  obtain  a
therapeutic effect.
40 The first natural hydroxa-
mate was TSA and is now considered as the
reference  compound  of  hydroxamate  based
inhibitors. Most of the synthetic hydroxamate
based HDACi target class I and class II with
high potency. SAHA has a potency at µM range
and has recently been approved for the treat-
ment  of  cutaneous  T-cell  lymphoma.  M-car-
boxycinamic acid bishydroxamide (CBHA) is
another  potent  second  generation  inhibitor
which  is  the  structural  basis  for  example
LAQ824  and  PXD101,  both  effective  at  nM
range  towards  classes  I  and  II.  Two  of  the
newest hydroxamate based HDACi are LBH589
and ITF2357 with very low IC50 values at nM
concentrations.
43,48 Benzamides  include  MS-
275 and CI-994 and are generally less potent
than  the  hydroxamates  and  cyclic  tetrapep-
tides. Cyclic tetrapeptides, include the natural
product depsipeptide (FK 228 or FR 901228)
and apicidin. Depsipeptide is a prodrug and
has to be metabolically activated via reduction
of the disulfite binding.
45 Recently KD5170, a
novel mercaptoketone-based histone deacety-
lase  inhibitor,  has  been  developed.  KD5170
showed  significant  anti-proliferative  activity
against a variety of human tumor cell lines,
including human MM cell lines.
44
Isoenzyme-selectivity of pan-HDACi and
mechanism of HDAC inhibition
In general, none of these inhibitors, except
tubacin, exhibit specificity towards one isoen-
zyme. However, they inhibit the enzyme activ-
ity of HDACs with varying efficiency (Table 1).
For  example,  depsipeptide  preferentially
inhibits HDAC1 and 2 compared to HDAC4 and
6, whereas the potency of MS-275 to inhibit
HDAC1 is 26 times higher compared to HDAC3
and appears to lack the ability to inhibit the
HDAC6 and 8.
45,49 Tubacin, the HDAC6 selective
inhibitor, induces hyperacetylation of α-tubu-
lin and has no effect on the histone acetylation
status, while other hydroxamate inhibitors like
TSA, SAHA and LBH589 induce histone – and
α-tubulin hyperacetylation.
42,50-52
X-ray  crystallographic  analyses  clarify  the
structure of an HDAC enzyme using an HDAC-
like protein (HDLP) isolated from an anaero-
bic bacterium, on the one hand and on the
other hand how inhibitors such as SAHA and
TSA mediate HDAC inhibition. The HDAC cat-
alytic  domain  consists  of  a  tube  like  pocket
whereby a Zn
2+ cation is positioned near the
bottom of this narrow pocket. The basic struc-
ture of the HDACi contains a cap group, an
aliphatic chain for a spacer, and a functional
group  (except  depsipeptide).  The  cap  group
may be necessary for packing the inhibitor at
the  rim  of  the  tube-like  active  site  pocket,
while the aliphatic group forms interactions
with the residues of the lining pocket. For TSA,
the  hydroxamic  acid  group  (the  functional
group) coordinates the zinc through its car-
bonyl and hydroxyl groups, resulting in the for-
mation of a penta-coordinated zinc and there-
by altering the activity of the enzyme.
53,54
Pre-clinical observations of
HDACi in multiple myeloma
Anti-myeloma activity of HDACi as
a single agent in vitro
HDACi modulate the gene expression
profile of multiple myeloma cells
Microarray  based  studies  showed  that
HDACi induce transcriptional modulations of
7-10 % of the genes in malignant cell lines by
acetylation of histones and non-histone pro-
teins.
55-57 The patterns of the HDACi induced
gene expression alterations are quite similar
for different HDAC inhibitors. Definite differ-
ences, however, could be observed by different
agents in different cancer cell lines.
58,59
In MM, the first cDNA array using SAHA in
the human MM1S cell line was performed by
Mitsiades et al. SAHA caused selective gene
expression alterations of oncogenes, prolifera-
tive/anti-apoptotic  transcription  factors,  cell
cycle regulators and members of the IGF-1R
and IL-6R signaling cascades.
55 Recently, gene
expression profiling of MM1S cells exposed to
VPA have also been performed and showed that
VPA also targeted genes involved in the cellu-
lar pathways crucial for the survival of the MM
cells  as  seen  for  SAHA.  Furthermore,  they
could demonstrate modulation of genes that
contribute  to  RNA  splicing/transcription  and
DNA replication, indicating that HDACi could
affect cell growth differently from apoptosis or
cell cycle regulation.
56
HDACi inhibit the proliferation of multiple
myeloma cells
Before investigating the molecular effect of
HDACi in certain human MM cell lines, assays
such  as  3-(4,5-dimethylthiazol-2-yl)-2,5-di  -
phenyl tetrazolium bromide (MTT)- or 3H-thy  -
midine incorporation assays were performed to
study the anti-proliferative effect of the HDACi.
Table 2 shows an overview of different HDACi
and their concentration range needed to inhib-
it the proliferation of the human MM cell lines
and/or primary human MM cells. 
HDACi  such  as  VPA,  FK228  and  ITF2357
affected the viability of IL-6 dependent as well
as IL-6 independent MM cell lines, indicating
Type of paper
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that the anti-myeloma activity of the HDACi is
not influenced by one of the key growth factors
in MM.
61,67,68 Furthermore, co-culturing the MM
cells with bone marrow stromal cells (BMSC)
does  not  protect  the  cells  from  cell  death
induced  by  the  HDACi  LAQ824,  ITF2357,
LBH589 or KD5170.
65,66,68,71 These data suggest
that  HDACi  could  overcome  the  protective
effect  of  the  BM  micro-environment.  The
MM1S  cells  were  resistant  to  KD5170  and
showed  no  increase  in  histone  acetylation,
whereas KD5170 sensitive cell lines exhibited
histone  hyperacetylation  after  KD5170  treat-
ment.
66This finding indicates that inhibition of
the HDAC enzymes is necessary for the anti-
tumor effects of the HDACi. 
JNJ-26481585,  a  recently  developed  novel
hydroxamate  based  HDACi  with  prolonged
pharmacodynamic  properties,  has  anti-prolif-
erative  effect  at  nM  concentrations  in  the
murine 5T33MM model.
72 This murine MM cell
line is derived from the 5TMM mouse model
which mimics the human disease closely at the
molecular, cellular and clinical level.
73,74
HDACi induce cell death in multiple myeloma
Besides  inhibition  of  proliferation,  HDACi
induced cell death is one of the major mecha-
nisms to inhibit the survival of the myeloma
cells.  Extrinsic  and  intrinsic  apoptotic  path-
ways as well as non-apoptotic cell death such as
autophagy have been reported in myeloma cells
treated with an HDACi. Figure 1 demonstrates
effects of the HDACi on the compounds of the
intrinsic and extrinsic apoptotic pathway.
The extrinsic apoptotic pathway is activated
by ligand binding to death receptors such as
Fas  (Apo-1  or  CD95),  tumor  necrosis  factor
receptor-1 (TNFR-1) and TNF-related apopto-
sis-inducing ligand (TRAIL or Apo2L) recep-
tors (DR4 and -5), resulting in activation of
caspase-8 and caspase-10. Apo2L/TRAIL inter-
acts with two death receptors (DR4 and DR5)
and  potently  induces  apoptosis  in  various
tumors, including primary MM cells and MM
cell lines, while exerting minimal or no toxici-
ty in normal cells.
75,76
Several  studies  have  demonstrated  that
HDACi can upregulate the expression of both
death receptors and their ligands and are pro-
posed to occur selectively in tumor cells.
77 The
U266 human MM cell line, although express-
ing significant levels of DR4 and caspase-8, is
resistant to Apo2L/TRAIL and this resistance
could be overcome with VPA. This sensitizing
effect of VPA is mediated by the redistribution
of DR4 to lipid rafts followed by an improved
DR4  signaling.
62 However,  opposite  results
have  been  obtained  by  Schwartz  et  al.  who
have demonstrated that VPA activated caspase-
3 but not caspase-9 and caspase-8 in the U266,
OPM2 and RPMI human MM cell lines.
63 In the
MM1S line, treated with LBH589, no upregula-
tion of death receptors and their ligands could
be observed. Caspase-8, however, was activat-
ed and the gene expression of the TOSA gene,
negative regulator of the Fas ligand (FasL) or
TRAIL induced apoptosis was downregulated.
69
SAHA sensitized MM1S cells to a Fas-activat-
ing monoclonal antibody CH-11 and to recom-
binant TRAIL. This sensitizing effect was asso-
ciated with decreased expression of the anti-
apoptotic protein FLICE-like inhibitory protein
(FLIP) and members of the inhibitors of apop-
tosis  (IAP)  family  such  as  X-linked  IAP
(XIAP).
64
Despite these results showing that HDACi
affect the extrinsic pathway, in MM and other
malignant cells it is still not clear how impor-
tant the death-receptor pathway is for the ther-
apeutic effects of HDACi.
The intrinsic apoptotic pathway is mediated
by the mitochondria whereby proapoptotic sig-
nals  result  in  the  release  of  mitochondrial
intermembrane proteins, such as cytochrome c
(cyto-c), apoptosis inducing factors (AIF) and
second mitochondria-derived activator of cas-
pase (Smac). Cytosolic cyto-c binds to apoptot-
ic protease activating factor (Apaf-1), resulting
in Apaf-1 oligomerization and subsequent cas-
pase-9 activation while cytosolic Smac binds to
XIAP  and  thereby  eliminates  its  inhibitory
effect on caspase-9. Cytosolic AIF induces cas-
pase-independent  apoptosis.
78 Members  from
the BCL2 family partially regulating this path-
way, contain the pro-apoptotic (e.g. Bax, Bak,
Bid  and  Bim)  and  anti-apoptotic  (e.g.  Bcl2,
BclxL and Mcl1) proteins. The BCL2 protein
Bid, can be cleaved by caspase-8 after death-
receptor  ligation,  and  truncated  Bid  (tBid)
localizes  to  the  mitochondria  to  initiate  the
intrinsic apoptotic pathway.
79
MM cells contain higher levels of the anti-
apoptotic proteins Bcl2 and Mcl1 and lower lev-
els of the pro-apoptotic protein Bax compared
to normal plasma cells.
76,78 These findings could
play a role in the survival of the MM cells and
the resistance to chemotherapeutic agents.
How HDACi activate the intrinsic apoptotic
cascade is cell context dependent and is still
not completely understood. Treatment of the
U266  MM  human  cell  line  and  primary  MM
human cells with depsipeptide resulted in a
decrease of the anti-apoptotic proteins Mcl1,
Table 1. Isoenzyme-selectivity of pan-HDACi.
Class Compound HDAC specificity Company/Sponsor Ref.
Short-chain fatty acid Butyrate Class I, IIa Merck 40
Valproic acid Class I, IIa NCI 41
Hydroxamate SAHA Class I, II Merck 40
PXD101 Class I, II CuraGen 40
LAQ824 Class I, II Novartis 40
LBH589 Class I, II Novartis 40
Tubacin Class IIb BI and MIT 42
ITF2357 Class I, II Italfarmaco 43
Mercaptoketone  KD5170 Class I, II Kalypsys 44
Cyclic tetrapeptide Depsipeptide Class I Gloucester 45
NCI: National Cancer Institute; BI: Broad Institute; MIT: Massachusetts Institute of Technology
Table 2. Potency of HDACi used in different in vitro MM models.
HDACi Range MM cells Ref.
NaB mM U266, RPMI 8226, ARH-77, OPM2 60
VPA mM OPM1, MM1S, DOX-40, INA-6, OPM2, 56, 61, 62, 63
NCI-H929, LP-1, RPMI 8226, U266
SAHA µM MM1S 55, 64
LAQ824 Sub-µM primary human MM cells, MM1S, 65
MM1R, RPMI 8226, -LR5, -MR20, -Dox40
KD5170 R MM1S 66 Sub-µM H929, U266, primary human MM cells
FK228 nM U266, RPMI 8266  67
ITF2357 nM CMA-03 68
LBH589 nM primary human MM cells, MM1S,  69
MM1R, U266, -LR7, -Dox40
MM1S: dexamethasone S, IL-6 independent; MM1R: dexamethasone R; RPMI 8226, OPM1, CMA-03, DOX-40: IL-6 independent; LR5: melphalan
R; MR20: mitoxantrone R; Dox40: doxorubicin R; U266: autocrine secretion of IL-6; INA-6, CMA-03: IL-6 dependent; OPM2: IL-6 dependent,
dexamethasone R when IL-6 is added; ARH-77: Epstein-Barr virus (EBV) positive cell line and thereby not considered as a genuine MM cell
line.
70 S: sensitive; R: resistantType of paper
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Bcl2, BclxL and an increase in Bax; this latter
could only be observed in primary human MM
cells.
67 ITF2357 induced apoptosis through the
intrinsic  pathway  rather  than  through  the
extrinsic pathway in the KMS18 MM cell line
since no cleavage of caspase-8 nor upregula-
tion of DR-4 have been found, whereas cleav-
age of caspase-3 and -9 and downregulation of
Bcl2 and Mcl1 could be demonstrated.
68 MM1S
cells treated with LBH589 underwent translo-
cation of cyto-c and AIF from the mitochondria
to the cytosol, upregulation of Apaf-1 and cleav-
age of Bid, caspase-9 and caspase-3. Further  -
more,  gene  expression  profiling  revealed  a
novel  apoptosis  and  caspase  activation
inhibitor, AVEN, which was downregulated by
treatment with LBH589.
69 These data represent
clear evidence that LBH589 caused cell death
through  mitochondrial  perturbations.  Both
LBH589 and SAHA induced poly (ADP-ribose)
polymerase (PARP) cleavage in MM cells by
two different enzymes, caspase-3 and calpain,
respectively.  Using  the  calpain  inhibitor,
calpeptin, and the caspase-3 inhibitor, benzy-
loxycarbonyl-Val-Ala-Asp  methylester-fluoro  -
me    thyl  ketone (z-VAD-fmk), they could demon-
strate in MM1S cells that the LBH589 induced
cell death is calpain-independent and partially
caspase-dependent,  while  the  SAHA  induced
cell death is calpain-dependent and caspase-
independent.
64,69 Furthermore, SAHA promotes
cleavage of Bid to tBid while overexpression of
the  anti-apoptotic  protein  Bcl2  inhibited
SAHA-induced  apoptotic  signaling.
64 Recent
data indicate that KD5170 mediates cell death
through  mitochondrial  perturbation  in  the
U266  cells.  KD5170  provoked  Bax  activation
and cleavage of caspase-9 and caspase-3, caus-
ing loss of mitochondrial membrane potential
and  subsequent  pro-apoptotic  factor  release.
The fact that AIF was released, and that the
nuclear condensation was partially blocked in
cells pre-treated with z-VAD-fmk before expo-
sure  to  the  HDACi,  suggest  that  KD5170
induced  apoptosis  through  both  caspase-
dependent  and  caspase-independent  path-
ways. Furthermore, KD5170 induced oxidative
stress and oxidative DNA damage in myeloma
cells as evidenced by the upregulation of heme
oxygenase-1  and  H2A.X  phosphorylation,
which  is  a  marker  of  DNA  double  strand
breaks.
66,80
Autophagy, an alternative model for apopto-
sis,  has  been  reported  to  contribute  to  the
HDACi induced cell death in several tumor cell
lines.
81,82 Autophagy  is  a  catabolic  process
involving  the  degradation  of  long-lived  pro-
teins or cytoplasmatic organelles through the
lysosomal machinery.
83 Schwartz et al. demon-
strated for the first time that autophagy might
be  involved  in  VPA  induced  cytotoxicity  in
human myeloma cell lines. Only cleavage of
caspase-3 and autophagic vacuoles in the cyto-
plasm could be observed in the myeloma cells
treated with VPA, indicating that autophagic
cell death might be involved.
63
HDACi induce cell cycle arrest
HDACi,  except  tubacin,  induce  cell  cycle
arrest  at  G1/S  phase.  The  events  in  the  G1
phase are coordinated by the three early G1 D
cyclins (1, 2, 3) and their associated cyclin-
dependent  kinases  (CDKs)  4/6  (G1  progres-
sion) and CDK 2 (G1/S transition). The tran-
scriptional regulation of the genes, necessary
for  G1  progression  and  G1/S  transition,
depends on the phosphorylation state of the
retinoblastoma (Rb) protein. Phosphorylation
of the Rb protein by G1 D cyclin/ cyclin-depend-
ent kinase (CDK) results in the release of E2F,
allowing  transcription  activation  and  further
progression  through  G1  and  initation  of  S
phase. The CDK inhibitors, including the INK4
family (p16) and the Cip/Kip family (p21, p27
and p57), are proteins that negatively regulate
the cell cycle by competing with the cyclin D -
CDK binding and therefore inhibiting the CDK
complex  kinase  activity.  In  MM,  constitutive
phosphorylation of the Rb protein may be fun-
damental to the growth and development of the
tumor.
52 The  mRNA  level  of  the  three  G1  D
cyclins are elevated in virtually all MM tumors
compared to healthy plasma cells and could be
due  to  an  Ig  translocation  or  an  unknown
mechanism.  The  elevated  levels  of  the  D
cyclins are not sufficient to promote a cell cycle
and need a corresponding increase of CDK4 or
CDK6.
84 Furthermore,  several  reports  have
demonstrated that p16 is frequently hyperme-
thylated in primary human MM cells. However,
no decreased mRNA could be found.
85,86
HDACi induce cell cycle arrest in the G1/S
phase which is mostly associated with induc-
tion of p21. This has been observed in the MM
cell  lines  treated  with  VPA,  NVP-LAQ824,
LBH589, NaB, SAHA and ITF2357.
60,61,64,65,68,69 MM
cells treated with VPA or LBH589 also showed
a reduction of cyclin D1 and/or cyclin D2, indi-
cating  that  induction  of  p21  is  not  solely
responsible for cycle arrest.
56,61
HDACi inhibit the aggresomal pathway
in multiple myeloma
The aggresomal protein degradation system
represents an alternative system to the protea-
some for degradation of polyubquitinated mis-
folded/unfolded  proteins  (Figure  2).
87 When
degradation of misfolded proteins exceeds the
proteasomal degradation through e.g. protea-
some inhibitors, proteins interact with other
unfolded or partially folded proteins, resulting
Article
Figure 1. Induction of the extrinsic and intrinsic apoptotic pathway by HDACi in myelo-
ma cells. The extrinsic apoptotic pathway is triggered by ligand binding and leads to acti-
vation of caspase-8, which, in turn, activates caspase-3. Activation of the intrinsic apop-
totic pathway results in the release of three compounds: (a) cytochrome-c (cyto-c) which
binds to apoptotic protease activating factor (Apaf-1) to activate caspase-9, (b) apoptosis
inducing factors (AIF) and (c) second mitochondria-derived activator of caspase (Smac).
FLICE-like inhibitory protein (FLIP) and members to the inhibitors of apoptosis (IAP)
are able to prevent apoptosis induced by death receptors or intrinsic pathway respective-
ly. Symbols denote compounds that are up-regulated (*), down-regulated (**), activated
(∏) or translocated to cytosol (r) by HDACi in myeloma cells.Article
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in  accumulation  of  ubiquitinylated  proteins,
organized  into  perinuclear  stuctures  termed
“aggresomes”.
88,89 Aggresomes  are  formed  by
the retrograde transport of the aggregated pro-
teins on microtubules (MT) and travel to the
MT organizing center (MTOC) region, where
they are sequestered as a single structure sus-
ceptible for lysosomal degradation. Movement
of  aggresomes  requires  intact  microtubules
and association with motor dynein. 
HDAC6 deacetylates alfa-tubulin and plays a
key role in the aggresomal pathway since it
can  bind  poly  ubiquitinated  proteins  and
dynein,  facilitating  the  transport  of  aggre-
somes  along  the  MTs.
32,90 Targeting  HDAC6
with tubacin or pan HDAC inhibitors such as
SAHA or LBH589, results in hyperacetylation of
alfa-tubulin, accumulation of polyubiquitinat-
ed  proteins  and  apoptosis.
71,91 It  has  been
shown that tubacin inhibits MM cell growth in
drug-sensitive  (MM1S,  U266,  INA-6  and
RPMI8226)  and  drug-resistant  cell  lines
(RPMI-LR5  and  RPMI-Dox40)  with  an  IC50
between 5-20 µM, whereas no cytotoxicity in
peripheral blood mononuclear cells (PBMCs)
could be observed at µM levels.
92 This indicates
that tubacin sensitivity is independent of drug
resistance and that tubacin selectively targets
malignant cells.
HDACi affect cytokines and proteins
implicated in multiple myeloma survival,
progression and immune escape
Mitsiades et al. showed that SAHA suppress-
es the expression of receptor genes involved in
MM cell proliferation, survival and/or migra-
tion such as IGF-1R, IL-6R and its key signal
transducer gp130, TNF-R, CD138 (syndecan-1)
and CXCR-4.
55Furthermore, in MM1S cells they
could  demonstrate  that  SAHA  suppressed
autocrine IGF-1 production and paracrine IL-6
secretion of BMSC by triggering MM cell bind-
ing.  This  suggests  that  SAHA  can  overcome
cell  adhesion-mediated  drug  resistance.
55,64
OPM-2 cells treated with NaB decreased IL-6R
but  when  cells  were  transfected  with  an
expression vector of IL-6R no decrease of the
receptor  could  be  observed.  Increased  p21
expression and apoptosis could be observed in
both transfected and untransfected cell lines,
indicating that downregulation of the IL-6R is
not required for the induction of p21 or apopto-
sis.
60 This  observation  again  confirms  that
HDACi act on multiple cellular pathways. 
Several  studies  provide  evidence  that
HDACi suppress angiogenesis through a direct
effect  on  the  growth  and  differentiation  of
endothelial cells on one hand and by down-reg-
ulating  the  expression  of  pro-angiogenic
genes in tumor cells on the other hand.
93-95 The
anti-angiogenic effect of HDACi in myeloma
has been demonstrated using OPM-2 and KM3
cells  treated  with  VPA.  VPA  decreases  VEGF
secretion  and  VEGF  receptor  expression,
resulting in inhibition of the vascular tubule
formation  of  endothelial  cells  in  co-cultures
with  myeloma  cells.  These  data  confirm  the
anti-angiogenic effect of HDACi on myeloma
which is important to suppress spread of the
MM cells.
61,96,97
Recently, De Bruyne et al. showed that the
tetraspanin CD9 which shows an inverse cor-
relation  between  its  expression  level  and
tumor metastasis in solid tumors, is epigenet-
ically down-regulated in MM and could be up-
regulated  by  treating  myeloma  cells  with
LBH589.  Myeloma  cells  expressing  CD9
become  more  susceptible  for  natural  killer
mediated cytolysis and the expression corre-
lates  with  non-active  MM  disease.  These
observations suggest that the immune escape
of the tumor cells and molecules, correlating
with the MM disease status, can be affected by
HDACi.
98
Anti-myeloma activity of HDACi in
combination therapy in vitro
Bortezomib
Bortezomib,  a  first-in-class,  potent  and
reversible proteasome inhibitor, has been suc-
cessfully  introduced  in  clinical  practice  and
represents  the  standard  of  care  in  sympto-
matic MM patients.
99 The anti-myeloma activi-
ty of bortezomib is a result of NF-ʺB inhibi-
tion, upregulation of various apoptotic path-
ways, and effects on the tumor micro-environ-
ment.
100-103 Pei et al. were the first to demon-
strate in vitro that HDACi in combination with
bortezomib resulted in an improved cytotoxic
effect compared to their effect as single agent.
Sequential exposure of U266 and MM1S cells
to  bortezomib  and  SAHA  or  NaB  potently
induced  caspase-3,  -8  and  -9  activation  and
release of the pro-apoptotic mitochondrial pro-
teins cyto-c and Smac, resulting in a synergis-
tic  induction  of  apoptosis.  This  effect  was
associated  with  a  reduction  in  NF-ʺB  DNA
binding activity, modulation of JNK activation
and a reactive oxygen species (ROS)-depend-
ent  downregulation  of  Cyclin  D1,  Mcl-1  and
XIAP.  Combining  bortezomib  with  PXD101
caused  oxidative  stress  accompanied  by  an
Figure 2. The aggresome pathway prevents accumulation of misfolded proteins. Unfolded
or misfolded proteins, that exceed proteasomal degradation, form aggregates and are
transported to the microtubule organizing center (MTOC) for degradation. This trans-
port requires HDAC6 which deacetylates alfa-tubulin and binds both polyubiquitinated
proteins and dynein. Inhibiting HDAC6 with tubacin, whether or not combined with the
proteasome inhibitor bortezomib, accumulates misfolded or unfolded proteins and leads
to apoptosis.Type of paper
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enhanced effect on Bim expression, DNA dam-
age, MAPK p38 activation and p53 phosphory-
lation. These observations indicate that there
are several molecular mechanisms that may
contribute to the synergy between bortezomib
and HDACi.
104 Specific inhibition of the aggre-
somal pathway by tubacin together with pro-
teasome inhibition by bortezomib also result-
ed in an accumulation of ubiquitinated pro-
teins followed by a synergistic anti MM-activi-
ty, mediated by stress-induced JNK activation,
followed by caspase/PARP cleavage.
92 In addi-
tion,  further  investigations  on  cytoskeletal
events showed that bortezomib alone lead to
aggresome formation and, combining it with
LBH589  or  SAHA,  both  inhibiting  HDAC6,
resulted in a disruption of aggresome forma-
tion  leading  to  apoptosis.
71,91 Nawrocki  et  al.
demonstrated that the oncogen Myc regulates
the sensitivity of MM cells to bortezomib in
combination with SAHA. Oncogenic activation
of Myc is a hallmark of nearly all rapidly divid-
ing malignant cells. In MM, the Myc expres-
sion  is  directly  correlated  with  intracellular
endoplasmatic  reticulum  (ER)  content  and
protein synthesis rate. Bortezomib in combi-
nation with SAHA resulted in an induction of
the pro-apoptotic BH3-only protein Noxa and
ER stress indicated by a disruption of calcium
homeostasis  and  activation  of  caspase-4.
Further  knock-down  studies  demonstrated
that caspase-4 and Noxa play significant roles
in Myc-driven sensitivity to the combination of
bortezomib and SAHA.
91
Enhanced anti-MM activity of the combina-
tion therapy could not only be observed in pri-
mary human MM cells but also in co-culture
conditions  and  conditions  with  exogenous
growth factors IL-6 or IGF-1. Taken together,
bortezomib in combination with HDACi may
represent  a  promising  therapeutic  strategy
that can overcome drug-resistance.
71,69,91,92
Death receptor ligands
In several tumor cells, an enhanced apoptot-
ic  effect  can  be  observed  using  HDACi  and
activators  of  the  TRAIL  and  Fas  pathway.
However, the molecular mechanism underly-
ing this synergism is still unclear and is cell-
type specific. 
Fandy et al. demonstrated that TSA, as well
as  SAHA,  in  combination  with  TRAIL  have
potent  synergistic  effect  in  the  ARO-1  MM
cells.
105 Similar  apoptotic  effects  have  been
observed in MM1S, U266 and H929 cell lines
treated with KD5170 and TRAIL.
66 The fact that
SAHA and TSA could up-regulate the two death
receptors DR4 and DR5 in the MM cells, cou-
pled with a downregulation of anti-apoptotic
proteins  (Bcl-2  and  XIAP)  could  explain  the
synergistic  effect  of  combination  therapy.
105
However, it has been shown that HDACi could
also  achieve  synergy  with  TRAIL  without
changing the TRAIL receptors or anti-apoptotic
proteins,  by  simultaneously  activating  the
intrinsic and extrinsic pathways.
40,106
DNA methyltransferase inhibitors
5-azacitidine  is  a  DNA  methyltransferase
inhibitor and shows activity against MM.
107 5-
azacitidine and analogs such as 5-azacytidine
(decitabine) are interesting tools to investi-
gate hypermethylation in tumorigenesis and
the  clinical  efficacy  is  currently  being
assessed in phase II trials.
108,109 Several investi-
gations have already shown that hypermethy-
lated tumor suppresor genes can be most effi-
ciently  reactivated  by  combining  DNA
demethylating agents with HDACi, this could
thereby  result  in  an  enhanced  reduction  of
tumor cell growth.
110-114
Treatment of the human myeloma cell line,
U266 with NaB and decitabine resulted in a G1
arrest, whereas no cell cycle arrest could be
observed when the compounds were used as
single agents. Also, the expression level of the
p16 gene on RNA and protein level was signif-
icantly increased when both epigenetic agents
were  applied  simultaneously.
115 Our  group
could  also  show  in  the  human  myeloma
Karpas707 cell line that the upregulation of the
pro-apoptotic protein Bim by LBH589 could be
enhanced  by  decitabine,  while  decitabine
alone had no effect on Bim expression.
116
Conventional therapeutic agents
LAQ824, depsipeptide and LBH589 showed
an enhanced decrease in survival of human
MM cell lines with the conventional therapeu-
tic agents such as dexamethasone and mel-
phalan.
65,67,69 Targeting different pathways could
contribute partially to the enhanced anti-MM
effect;  namely  caspase-8  is  activated  by
LAQ824 and not by dexamethasone whereby
combining both agents provides an additional
apoptotic signal to those already induced by
dexamethasone.  Further  investigations  are
needed to clarify the molecular mechanism of
the  synergism  between  chemotherapeutic
agents and HDACi.
Anti-myeloma activity of HDACi in
vivo
To study the pathogenesis of MM and to find
new  treatment  strategies,  different  animal
models have been developed, each with their
own advantages and disadvantages.
73
To  determine  whether  in  vivo  the  anti-
myeloma effects of LAQ824, VPA and KD5170
correlate with their in vitro activity, human
MM  xenografts  in  immunodeficient  mice
were  used.  Xenograft  murine  models  were
subcutaneously  injected  with  RPMI8226,
OPM1  or  H929  and  daily  treatment  with
LAQ824, VPA or KD5170, respectively, started
when tumors were measurable. These in vivo
studies resulted in a significant decrease in
tumor growth and a significant increase in
survival of mice treated with the HDACi.
65-67
Furthermore,  the  enhanced  anti-myeloma
activity of LBH589 with bortezomib could be
demonstrated in vivo by Atadja et al. using a
disseminated  luciferized  MM1S  MM  xeno  -
graft mouse model.
117 One of the major limita-
tions of these in vivo experiments is the lack
of the interaction of MM cells with a human
micro-environment and therefore a protective
effect of the BM micro-environment against
the  anti-myeloma  activity  of  the  HDACi  in
vivo cannot be excluded.
Recently,  the  syngeneic  murine  5T33  and
5T2MM  models,  which  mimic  the  human
myeloma  disease  closely,  have  been  used  to
investigate  the  anti-myeloma  activity  of  JNJ-
26481585.
74 Injecting C57Bl/KaLwRij mice with
5T2 or 5T33MM cells results in a migration of
the  MM  cells  to  the  BM  followed  by  tumor
growth, induction of angiogenesis and induc-
tion of a MM bone disease (only in the 5T2MM
model).  5T2  and  5T33MM  mice  treated  with
JNJ-26481585 resulted in a significant decrease
in tumor load and a reduction in the MM bone
disease.
72 Moreover, when a very low dose of
JNJ-26481585 was combined with bortezomib,
MM bone disease was more reduced than seen
with bortezomib alone (Deleu et al., personal
observations,  2009). These  in  vivo  studies
demonstrated that the antimyeloma activity of
the HDACi as single agents or in combination
with bortezomib could not be overcome by the
BM micro-environment.
Clinical observations of HDACi
in multiple myeloma
Several clinical trials with HDACi alone or
in combination with other antimyeloma agents
are ongoing (Table 3).
118-125 Phase I clinical tri-
als showed that HDACi, such as SAHA, LBH589
and depsipeptide are well tolerated in myeloma
patients. In phase II clinical trials, the activity
of  the  HDACi  as  single  agent  was  limited.
However, combining HDACi with dexametha-
sone  and/or  bortezomib  resulted  in  a  more
promising therapeutic setting in the treatment
of MM, even in patients with refractory and
relapsed MM.
Future directions
It has become clear that pan-HDACi have
anti-neoplastic activities by affecting multiple
pathways  involved  in  cell  growth,  survival,
immune  response  and  tumor  vasculature.
However, the precise underlying mechanism of
the inhibition of the different HDACs by pan-
HDACi and their biological role in MM patho-
genesis  remain  to  be  clarified.  A  greater
Articleunderstanding of the molecular effects of the
HDACi and the role of HDACs is essential in
selecting  patients  who  are  potential  candi-
dates for HDACi therapy and in designing com-
bination studies. The development of isoform-
specific inhibitors would be a valuable tool to
investigate  the  biological  role  of  specific
HDACs. However, it is still not clear whether
selective inhibition of HDACs has therapeutic
advantages over a pan-HDACi. Clinical trials
demonstrated promising anti-tumor responses
to HDACi, mainly in combination with other
agents such as bortezomib or dexamethasone
which are already in clinical use. Therefore,
the development of new and improved HDACi
should be encouraged together with their use
in  combination  therapy  to  improve  the  out-
come for MM patients. 
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